8-K filing — Aprea Therapeutics, Inc. (APRE)
Filed: 2026-08-28 AccNo: 0001104659-26-102795 Size: 182 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Aprea Therapeutics Q2 EPS $(0.07) Beats $(0.23) Estimate
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.23) by 69.57 percent. This is a 86.79 percent increase over losses of $(0.53) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Aprea Therapeutics Expands Current Patent Portfolio
Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $6 to $3.